
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12061934/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies. Urologia Internationalis, 2022, 106, 75-82.	0.6	4
2	Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study. Minerva Urology and Nephrology, 2022, 73, .	1.3	4
3	Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette–Guerin Immunotherapy. Diagnostics, 2022, 12, 586.	1.3	14
4	Outcomes of Robot-assisted Partial Nephrectomy for Clinical T3a Renal Masses: A Multicenter Analysis. European Urology Focus, 2021, 7, 1107-1114.	1.6	17
5	Subcellular Localization of uc.8+ as a Prognostic Biomarker in Bladder Cancer Tissue. Cancers, 2021, 13, 681.	1.7	12
6	Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. Frontiers in Oncology, 2021, 11, 651745.	1.3	11
7	Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. Translational Andrology and Urology, 2021, 10, 626-635.	0.6	20
8	Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project). World Journal of Urology, 2020, 38, 151-158.	1.2	23
9	Near-infrared Fluorescence Imaging with Indocyanine Green in Robot-assisted Partial Nephrectomy: Pooled Analysis of Comparative Studies. European Urology Focus, 2020, 6, 505-512.	1.6	35
10	Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with International Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies. World Journal of Urology, 2020, 39, 1861-1867.	1.2	14
11	Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 459-464.	0.8	42
12	Effect of Obesity and Overweight Status on Complications and Survival After Minimally Invasive Kidney Surgery in Patients with Clinical T ₂₋₄ Renal Masses. Journal of Endourology, 2020, 34, 289-297.	1.1	9
13	Robotic partial nephrectomy versus radical nephrectomy in elderly patients with large renal masses. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 99-108.	3.9	28
14	Outcomes and predictors of benign histology in patients undergoing robotic partial or radical nephrectomy for renal masses: a multicenter study. Central European Journal of Urology, 2020, 73, 33-38.	0.2	3
15	An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World Journal of Urology, 2019, 37, 507-514.	1.2	77
16	Outcomes of Partial and Radical Nephrectomy in Octogenarians – A Multicenter International Study (Resurge). Urology, 2019, 129, 139-145.	0.5	9
17	Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA) Tj ETQq1 1 0.7	84314 rgBT 1.2	/Oyerlock 10

Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non–muscle-invasive Urothelial Bladder Cancer. European Urology Oncology, 2018, 1, 403-410.

2.6 66

#	Article	IF	CITATIONS
19	Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer. Journal of Cancer, 2018, 9, 4250-4254.	1.2	26
20	Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity. Journal of Experimental and Clinical Cancer Research, 2018, 37, 297.	3.5	11
21	Microbiota effects on cancer: from risks to therapies. Oncotarget, 2018, 9, 17915-17927.	0.8	155
22	Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). European Urology, 2018, 74, 226-232.	0.9	109
23	Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non–muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 445-452.	0.9	55
24	Exploring the molecular aspects associated with testicular germ cell tumors: a review. Oncotarget, 2018, 9, 1365-1379.	0.8	21
25	Outcomes of Laparoscopic and Robotic Partial Nephrectomy for Large (>4ÂCm) Kidney Tumors: Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2017, 24, 2420-2428.	0.7	18
26	The emerging role of obesity, diet and lipid metabolism in prostate cancer. Future Oncology, 2017, 13, 285-293.	1.1	55
27	Epithelial-mesenchymal transition in prostate cancer: an overview. Oncotarget, 2017, 8, 35376-35389.	0.8	162
28	Micrornas in prostate cancer: an overview. Oncotarget, 2017, 8, 50240-50251.	0.8	113
29	Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer. Oncotarget, 2017, 8, 77110-77120.	0.8	59
30	Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. Oncotarget, 2017, 8, 18424-18434.	0.8	52
31	Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX. BioMed Research International, 2016, 2016, 1-11.	0.9	43
32	New Cross-Talk Layer between Ultraconserved Non-Coding RNAs, MicroRNAs and Polycomb Protein YY1 in Bladder Cancer. Genes, 2016, 7, 127.	1.0	26
33	From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples. Frontiers in Pharmacology, 2016, 7, 110.	1.6	4
34	Tumour biomarkers: homeostasis as a novel prognostic indicator. Open Biology, 2016, 6, 160254.	1.5	21
35	Multiparametric MRI for prostate cancer detection: Preliminary results on quantitative analysis of dynamic contrast enhanced imaging, diffusion-weighted imaging and spectroscopy imaging. Magnetic Resonance Imaging, 2016, 34, 839-845.	1.0	21
36	Biomarkers in localized prostate cancer. Future Oncology, 2016, 12, 399-411.	1.1	39

#	Article	IF	CITATIONS
37	Achievement of trifecta in minimally invasive partial nephrectomy correlates with functional preservation of operated kidney: a multi-institutional assessment using MAG3 renal scan. World Journal of Urology, 2016, 34, 925-931.	1.2	26
38	PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. World Journal of Urology, 2016, 34, 485-493.	1.2	41
39	Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. Oncotarget, 2016, 7, 85641-85649.	0.8	22
40	Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis. Oncotarget, 2016, 7, 20636-20654.	0.8	66
41	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy. Medicine (United States), 2015, 94, e1861.	0.4	43
42	Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 163.e15-163.e23.	0.8	40
43	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. Future Oncology, 2015, 11, 3091-3098.	1.1	17
44	Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine. Anticancer Research, 2015, 35, 1017-23.	0.5	35
45	Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion. Journal of Experimental and Clinical Cancer Research, 2014, 33, 48.	3.5	24
46	Robotic Versus Laparoscopic Adrenalectomy: A Systematic Review and Meta-analysis. European Urology, 2014, 65, 1154-1161.	0.9	167
47	Multiparametric MRI for prostate cancer detection: Performance in patients with prostate-specific antigen values between 2.5 and 10 ng/mL. Journal of Magnetic Resonance Imaging, 2014, 39, 1206-1212.	1.9	21
48	Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with "gray―prostate-specific antigen levels at first biopsy: systematic review and meta-analysis. Translational Research, 2014, 164, 444-451.	2.2	48
49	Current Applications of Near-infrared Fluorescence Imaging in Robotic Urologic Surgery: A Systematic Review and Critical Analysis of the Literature. Urology, 2014, 84, 751-759.	0.5	47
50	Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate, 2013, 73, 227-235.	1.2	58
51	Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study. Journal of Translational Medicine, 2013, 11, 161.	1.8	36
52	EGFR mutational status in penile cancer . Expert Opinion on Therapeutic Targets, 2013, 17, 501-505.	1.5	14
53	Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 761-765.	0.8	16
54	Regulatory T cells, interleukin (IL)-6, IL-8, Vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. BJU International, 2013, 112, 686-696.	1.3	70

SISTO PERDONÃ

#	Article	IF	CITATIONS
55	Comment on: EGFR mutational status in Brazilian patients with penile carcinoma. Expert Opinion on Therapeutic Targets, 2013, 17, 857-859.	1.5	2
56	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Future Oncology, 2013, 9, 889-897.	1.1	38
57	Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2–10 ng/ml. PLoS ONE, 2013, 8, e67687.	1.1	87
58	Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms. Oncology Reports, 2012, 27, 409-15.	1.2	17
59	Cisplatin and 5â€fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU International, 2012, 110, E661-6.	1.3	76
60	Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clinica Chimica Acta, 2012, 413, 1274-1278.	0.5	51
61	Phase II study of docetaxel reâ€ŧreatment in docetaxelâ€pretreated castrationâ€resistant prostate cancer. BJU International, 2011, 107, 234-239.	1.3	82
62	Prostate Cancer Detection in the "Grey Area―of Prostate-Specific Antigen Below 10 ng/ml: Head-to-Head Comparison of the Updated PCPT Calculator and Chun's Nomogram, Two Risk Estimators Incorporating Prostate Cancer Antigen 3. European Urology, 2011, 59, 81-87.	0.9	73
63	Paclitaxel in Pretreated Metastatic Penile Cancer: Final Results of a Phase 2 Study. European Urology, 2011, 60, 1280-1284.	0.9	73
64	Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. Cancer Chemotherapy and Pharmacology, 2011, 67, 1455-1461.	1.1	24
65	Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. Anti-Cancer Drugs, 2010, 21, 101-106.	0.7	19
66	Reply to Emmanuele A. Jannini's Words of Wisdom re: The Role of Short Frenulum and the Effects of Frenulectomy on Premature Ejaculation [J Sex Med 2010;7:1269–76]. Eur Urol 2010;57:1119–20. European Urology, 2010, 58, e49-e50.	0.9	1
67	Original Research—Ejaculatory Disorders: The Role of Short Frenulum and the Effects of Frenulectomy on Premature Ejaculation. Journal of Sexual Medicine, 2010, 7, 1269-1276.	0.3	20
68	Four-Year Outcome of a Prospective Randomised Trial Comparing Bipolar Plasmakinetic and Monopolar Transurethral Resection of the Prostate. European Urology, 2009, 55, 922-931.	0.9	97
69	Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. Anti-Cancer Drugs, 2009, 20, 277-280.	0.7	11
70	Bladderâ€sparing, combinedâ€modality approach for muscleâ€invasive bladder cancer. Cancer, 2008, 112, 75-83.	2.0	83
71	Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study. European Urology, 2008, 54, 1089-1096.	0.9	121
72	Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study. European Urology, 2007, 52, 1020-1027.	0.9	15

#	Article	IF	CITATIONS
73	Gyrus bipolar versus standard monopolar transurethral resection of the prostate: A randomized prospective trial. Urology, 2006, 67, 69-72.	0.5	120
74	Renal cell carcinoma with solitary toe metastasis. International Journal of Urology, 2005, 12, 401-404.	0.5	33
75	Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncology, The, 2005, 6, 295-300.	5.1	108
76	Management of gynaecomastia in patients with prostate cancer: a systematic review. Lancet Oncology, The, 2005, 6, 972-979.	5.1	49
77	Dynamic sentinel node biopsy in clinically node-negative penile cancer versus radical inguinal lymphadenectomy: A comparative study. Urology, 2005, 66, 1282-1286.	0.5	64
78	Weekly Docetaxel and Vinorelbine (VIN-DOX) as First Line Treatment in Patients with Hormone Refractory Prostate Cancer. European Urology, 2004, 46, 712-716.	0.9	16